Navigation Links
Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
Date:6/10/2013

BURLINGTON, Mass., June 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most influence over surveyed U.S. and European oncologists' prescribing decisions for platinum-resistant advanced ovarian cancer. The emerging agents for this indication—Roche/Genentech/Chugai's Avastin (which is already approved in Europe for recurrent platinum-sensitive ovarian cancer), Amgen/Takeda Pharmaceutical's trebananib, Merck/Endocyte's vintafolide and AstraZeneca's olaparib—are all expected to offer efficacy advantages over currently available therapies used to treat platinum-resistant advanced ovarian cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled Ovarian Cancer (Platinum-Resistant Advanced): Are Emerging Targeted Therapies Poised to Fill the Significant Unmet Need for This Difficult-to-Treat Patient Population?, finds that surveyed U.S. oncologists would prescribe Avastin in combination with either weekly paclitaxel (Bristol-Myers Squibb's Taxol, generics) or Janssen Biotech's Doxil/Caelyx to a total of 55 percent of their drug-treated patients with platinum-resistant advanced ovarian cancer.

The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in progression-free survival (PFS) in this patient population. Based on clinical data and thought-leader opinion, Avastin in combination with chemotherapy is in position to offer the PFS benefit that the majority of surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.

"The platinum-resistant advanced ovarian cancer population represents a patient population with high unmet need," said Decision Resources Senior Analyst Gemma McConnell, Ph.D. "Current treatment consists of a non-platinum chemotherapy monotherapy, which typically result in low tumor response rates and a short progression-free interval. Taking together positive Phase III clinical data and interviewed experts' opinion, Avastin in combination with chemotherapy is poised to address this unmet need."

About Decision Resources
Decision Resources ( www.decisionresources.com ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
2. Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
4. NextDocs Launches QuickStart for Emerging Growth Companies
5. Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
6. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
7. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
8. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
9. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
10. Emerging Precision Medicine Powerhouse Changes Name to Increase Visibility and Overall Awesomeness
11. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 The U.S. Food and Drug ... Kit, performed on the Pheno System. This is ... bloodstream infections and provide information about which antibiotics ... sensitivity). The test also reduces the amount of ... which can guide antibiotic treatment recommendations more quickly. ...
(Date:2/24/2017)...  This report analyzes the worldwide markets for Chiral ... Products: Intermediates, Analytical, and Others. The End Use ... Agrochemicals. The report provides separate comprehensive analytics for the ... , and Rest of World. Annual estimates and ... Also, a six-year historic analysis is provided for these ...
(Date:2/24/2017)... , Feb 24, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for ... engaged in or interested in palliative care education and research. The Symposium, “Innovate. ... North County San Diego on Sept. 28 and 29, 2017, on the campus of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... The 89th Academy Awards will be celebrated this weekend, ... Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” ... is the Center for American Progress (CAP), for its report, Lessons From State Performance ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. ... are sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental ... card for a dinner for two at the Cheesecake Factory. , Tickets are ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC announces ... and explore the world from different perspectives. By providing a place for people ... understanding, increase empathy, and find greater happiness. , "Our approach to structuring ...
Breaking Medicine News(10 mins):